Previous close | 0.4800 |
Open | 0.6000 |
Bid | 0.4000 |
Ask | 0.9000 |
Strike | 55.00 |
Expiry date | 2024-07-19 |
Day's range | 0.4000 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | 452 |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...